GLP-1 patches for weight loss have made the scene—but a leading MD warns you they aren't the same as the more familiar ...

Novo Nordisk announced its oral GLP-1 has been approved by the FDA to reduce risk for major adverse cardiovascular events in ...

Glucagon-like peptide 1 receptor agonists (GLP-1RA) have made waves as treatments for obesity and type 2 diabetes, but a new report suggests they might also have clinical benefits for certain patients ...

The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of ...

A new class of weight-loss drug has shown it can significantly boost weight loss when paired with GLP-1 therapy – without ...

Semaglutide 7 mg and 14 mg tablets are now available for reducing the risk of cardiovascular death, heart attack, or stroke ...

Clinical Director of the National Institute of Drug Abuse Dr. Lorenzo Leggio, said GLP-1 drugs' effect on the brain can help ...

USA: A study published in Obesity Pillars has revealed that individuals taking GLP-1 receptor agonists (GLP-1RAs) experienced ...

Patient selection should prioritize those with obesity and heart failure with preserved ejection fraction, as benefits for reduced ejection fraction are not yet proven.

GLP-1 receptor agonist therapy reduced surgical abscess repairs and hospitalizations among people with hidradenitis ...

People are trying mini doses of GLP-1 drugs to lose weight or maintain weight loss, but doctors urge caution, calling the ...

Terns Pharmaceuticals' trial data from its oral GLP-1 treatment for obesity missed a high threshold for efficacy, safety and tolerability. The biopharmaceutical company said Tuesday it will not ...